ALNYLAM PHARMACEUTICALS, INC. Equity Method Investment, Summarized Financial Information, Revenue (Deprecated 2020-01-31)
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Equity Method Investment, Summarized Financial Information, Revenue (Deprecated 2020-01-31) of $9.46 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-19.
Discontinued › Income Statement › Other Income
us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue · last filed 2015-02-13
- ALNYLAM PHARMACEUTICALS, INC. equity method investment, summarized financial information, revenue (deprecated 2020-01-31) for the quarter ending 2012-12-31 was $0.00, a 100.00% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. equity method investment, summarized financial information, revenue (deprecated 2020-01-31) for the quarter ending 2012-09-30 was $2.71M, a 28.72% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. equity method investment, summarized financial information, revenue (deprecated 2020-01-31) for the quarter ending 2012-06-30 was $3.21M, a 2.90% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. equity method investment, summarized financial information, revenue (deprecated 2020-01-31) for the quarter ending 2012-03-31 was $3.54M.
- ALNYLAM PHARMACEUTICALS, INC. equity method investment, summarized financial information, revenue (deprecated 2020-01-31) for fiscal 2012 was $9.46M, a 31.38% decline from fiscal 2011.
- ALNYLAM PHARMACEUTICALS, INC. equity method investment, summarized financial information, revenue (deprecated 2020-01-31) for fiscal 2011 was $13.79M, a 60.32% increase from fiscal 2010.
- ALNYLAM PHARMACEUTICALS, INC. equity method investment, summarized financial information, revenue (deprecated 2020-01-31) for fiscal 2010 was $8.60M.
| Period end | Equity Method Investment, Summarized Financial Information, Revenue (Deprecated 2020-01-31) 3 month | Equity Method Investment, Summarized Financial Information, Revenue (Deprecated 2020-01-31) 6 month | Equity Method Investment, Summarized Financial Information, Revenue (Deprecated 2020-01-31) 9 month | Equity Method Investment, Summarized Financial Information, Revenue (Deprecated 2020-01-31) 9 month as first filed | Equity Method Investment, Summarized Financial Information, Revenue (Deprecated 2020-01-31) 12 month |
|---|---|---|---|---|---|
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-K 9 month · filed 2013-02-19 | $2.71M derived: sum of 2 quarters · filed 2013-02-19 | $5.93M derived: sum of 3 quarters · filed 2013-02-19 | $9.46M 10-K · filed 2013-02-19 | |
| 2012-09-30 | $2.71M 10-Q · filed 2012-11-05 | $5.93M derived: sum of 2 quarters · filed 2012-11-05 | $9.46M 10-K · filed 2015-02-13 | $9.37M 10-Q · filed 2012-11-05 | $12.82M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-06-30 | $3.21M 10-Q · filed 2012-08-08 | $6.65M 10-Q · filed 2012-08-08 | $10.11M derived: sum of 3 quarters · filed 2014-02-20 | $13.92M derived: sum of 4 quarters · filed 2014-02-20 | |
| 2012-03-31 | $3.54M derived: 10-K 12 month − 3 quarters · filed 2013-02-19 | $6.90M derived: sum of 2 quarters · filed 2014-02-20 | $10.71M derived: sum of 3 quarters · filed 2014-02-20 | $14.02M derived: sum of 4 quarters · filed 2014-02-20 | |
| 2011-12-31 | $3.36M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | $7.17M derived: sum of 2 quarters · filed 2014-02-20 | $10.48M derived: sum of 3 quarters · filed 2014-02-20 | $13.79M 10-K · filed 2014-02-20 | |
| 2011-09-30 | $3.81M 10-Q · filed 2012-11-05 | $7.12M derived: sum of 2 quarters · filed 2012-11-05 | $10.43M 10-Q · filed 2012-11-05 | ||
| 2011-06-30 | $3.31M 10-Q · filed 2012-08-08 | $6.62M 10-Q · filed 2012-08-08 | |||
| 2010-12-31 | $8.60M 10-K · filed 2013-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |